Wegovy Maker to Limit Starter-Dose Supplies in U.S. as Demand Surges

Danish pharmaceuticals giant Novo Nordisk says it is adding capacity but warns supply shortfalls are likely to continue

The Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand.

The Food and Drug Administration cleared Wegovy, made by Novo Nordisk, as a treatment for chronic weight management in 2021. It has since exploded in popularity.